An aldose reductase inhibitor
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

AT-001

Item No. 36105

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
7,8-dihydro-8-oxo-7-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-pyrazino[2,3-d]pyridazine-5-acetic acid
CAS Number
1355612-71-3
Synonyms
  • Caficrestat
Molecular Formula
C17H10F3N5O3S
Formula Weight
421.4
Purity
≥98%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: soluble
λmax
221, 257 nm
SMILES
O=C(CC1=NN(CC2=NC3=C(S2)C=CC(C(F)(F)F)=C3)C(C4=NC=CN=C41)=O)O
InChi Code
InChI=1S/C17H10F3N5O3S/c18-17(19,20)8-1-2-11-9(5-8)23-12(29-11)7-25-16(28)15-14(21-3-4-22-15)10(24-25)6-13(26)27/h1-5H,6-7H2,(H,26,27)
InChi Key
YRGPAXAVTDMKDK-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $35

    Add

    5 mg

    $149

    Add

    10 mg

    $228

    Add

    25 mg

    $394

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    AT-001 is an inhibitor of aldose reductase (IC50 = 28.9 pM).1 It reduces infarct area in streptozotocin-induced diabetic mice expressing human aldose reductase in a model of cardiomyopathy induced by ischemia-reperfusion injury when administered at a dose of 40 mg/kg.2

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Wasmuth, A., Landry, D., Deng, S.X., et al. Aldose reductase inhibitors and uses thereof. (2014).

    2. Perfetti, R., Rowell, P., Shendelman, S., et al. Preclinical and clinical proof of concept for metabolic intervention in diabetic cardiomyopathy. J. Card. Fail. 25(8), S77 (2019).